1,019 reports of this reaction
2.1% of all FOSAPREPITANT DIMEGLUMINE reports
#6 most reported adverse reaction
FATIGUE is the #6 most commonly reported adverse reaction for FOSAPREPITANT DIMEGLUMINE, manufactured by Merck Sharp & Dohme LLC. There are 1,019 FDA adverse event reports linking FOSAPREPITANT DIMEGLUMINE to FATIGUE. This represents approximately 2.1% of all 48,249 adverse event reports for this drug.
Patients taking FOSAPREPITANT DIMEGLUMINE who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is a less commonly reported adverse event for FOSAPREPITANT DIMEGLUMINE, but still significant enough to appear in the safety profile.
In addition to fatigue, the following adverse reactions have been reported for FOSAPREPITANT DIMEGLUMINE:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 1,019 FDA reports for FOSAPREPITANT DIMEGLUMINE. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 2.1% of all adverse event reports for FOSAPREPITANT DIMEGLUMINE, making it a notable side effect.
If you experience fatigue while taking FOSAPREPITANT DIMEGLUMINE, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.